Completed PHASE3 INTERVENTIONAL 2-arm NCT00483054

Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin (N2R)

Sponsor: Bamrasnaradura Infectious Diseases Institute

Updated 5 times since 2017 Last updated: Nov 21, 2011 Started: Jan 31, 2007 Primary completion: Dec 31, 2008 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates HIV Infections and Tuberculosis and is currently completed. Bamrasnaradura Infectious Diseases Institute leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bamrasnaradura Infectious Diseases Institute
Chulalongkorn University
Mahidol University

Data source: Bamrasnaradura Infectious Diseases Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nonthaburi, Thailand